• head_banner_01

Quality Inspection for Cephapirinbenzathine - Ganirelix Acetate Peptide API – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our company for the long-term to develop together with customers for mutual reciprocity and mutual benefit for Low Potassium High Chloride, Isonicotinic Acid, Sodium Thioglycolate, We focus on for making superb top quality goods to provide support for our purchasers to ascertain long-term win-win romantic relationship.
Quality Inspection for Cephapirinbenzathine - Ganirelix Acetate Peptide API – Gentolex Detail:

Product Detail

Name  Ganirelix Acetate
CAS number  123246-29-7
Molecular formula  C80H113ClN18O13
Molecular weight  1570.34

Synonyms

Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2;Ganirelixum;ganirelix Acetate; GANIRELIX; Ganirelix Acetate USP/EP/

Description

Ganirelix is a synthetic decapeptide compound, and its acetate salt, Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. The amino acid sequence is: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-Tyr-D-HomoArg(9,10-Et2)-Leu-L-HomoArg(9,10-Et2)-Pro-D- Ala-NH2. Mainly clinically, it is used in women undergoing assisted reproductive technology controlled ovarian stimulation programs to prevent premature luteinizing hormone peaks and to treat fertility disorders due to this cause. The drug has the characteristics of less adverse reactions, high pregnancy rate and short treatment period, and has obvious advantages compared with similar drugs in clinical practice.

Pharmacological Action

The pulsatile release of gonadotropin-releasing hormone (GnRH) stimulates the synthesis and secretion of LH and FSH. The frequency of LH pulses in the mid and late follicular phases is approximately 1 per hour. These pulses are reflected in transient rises in serum LH. During mid-menstrual period, the massive release of GnRH causes a surge of LH. The midmenstrual LH surge can trigger several physiological responses, including: ovulation, oocyte meiotic resumption, and corpus luteum formation. The formation of the corpus luteum causes serum progesterone levels to rise, while estradiol levels fall. Ganirelix acetate is a GnRH antagonist that competitively blocks GnRH receptors on pituitary gonadotrophs and subsequent transduction pathways. It produces a rapid, reversible inhibition of gonadotropin secretion. The inhibitory effect of ganirelix acetate on pituitary LH secretion was stronger than that on FSH. Ganirelix acetate failed to induce the first release of endogenous gonadotropins, consistent with antagonism. Complete recovery of pituitary LH and FSH levels occurred within 48 hours after ganirelix acetate was discontinued.


Product detail pictures:

Quality Inspection for Cephapirinbenzathine - Ganirelix Acetate Peptide API – Gentolex detail pictures

Quality Inspection for Cephapirinbenzathine - Ganirelix Acetate Peptide API – Gentolex detail pictures


Related Product Guide:

With a positive and progressive attitude to customer's interest, our enterprise continually improves our products excellent to meet the wants of customers and further focuses on safety, reliability, environmental requirements, and innovation of Quality Inspection for Cephapirinbenzathine - Ganirelix Acetate Peptide API – Gentolex , The product will supply to all over the world, such as: Portugal, Congo, Swedish, Our company has always insisted on the business principle of "Quality, Honest, and Customer First" by which we have won the trust of clients both from at home and abroad. If you are interested in our solutions, you should do not hesitate to contact us for further information.
  • As a veteran of this industry, we can say that the company can be a leader in the industry, select them is right.
    5 Stars By Samantha from Seattle - 2017.07.07 13:00
    We are really happy to find such a manufacturer that ensuring product quality at the same time the price is very cheap.
    5 Stars By Diana from Iran - 2018.06.30 17:29
    Write your message here and send it to us